CD79A and metabolic syndrome: In this study, we showed that the LDP treatment during early life disturbed GM composition, resulting in a persistent inhibition of the intestinal IgA response and a decrease in intestinal sIgA, which led to a disruption in the ileal bacterial composition, increases in bacterial encroachment and adipose inflammation, and an enhancement of diet-induced MetS.